Neuroendocrine Tumor Market

Neuroendocrine tumors are rare. However, during past decade NETs incidence is on a rise. DelveInsight’s Neuroendocrine Tumors Market Insights, Epidemiology and Market Forecast — 2027 provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. DelveInsight’sestimates show that the total Neuroendocrine Tumor prevalent population in 7 Major Markets was 4, 42,100 and total NET incident cases were 44,070 in 2016. United States reported higher NET prevalence with 1, 93,877 cases in 2016, followed by EU5 and Japan. Among EU5, Germany had the highest prevalent population of NETwhile Spain had the lowest. NET is known to affect males more predominant as compared to females. The report provides historical as well as forecasted Neuroendocrine Tumors epidemiology, Neuroendocrine Tumors prevalent cases, symptom based classification of NETs (asymptomatic and symptomatic), diagnosed prevalence based on malignancy (Malignant and non-malignant), site specific incident cases (Gastroenteropancreatic, lung and other sites), Grade-wise prevalent cases (Grade I, Grade II and Grade III) and stage-wise prevalent cases (localized, regional and distant)] scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016–2027. The rise in global NET incidence can be attributed to better diagnostic methods and advances in medical sector. NETs can develop at any age but the average age of diagnosis is around 50–60 years.

Comments

Popular posts from this blog

Cyclin-dependent kinase

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Smoking Cessation Market Research Report 2030 | Smoking Cessation Market